Cardinal Health Reports Fiscal 2013 Second-Quarter Cardinal Health Reports Fiscal 2013 Second-Quarter Results
- Operating earnings increase 13 percent to $506 million, or 11 percent to $525 million on a non-GAAP basis(1)
- Diluted earnings per share from continuing operations increase 16 percent to $0.88, or 15 percent to $0.93 on a non-GAAP basis
- Fiscal 2013 non-GAAP earnings per share guidance tightened to $3.42 to $3.50, representing top half of prior range
DUBLIN, Ohio, Feb. 5, 2013 /PRNewswire/ -- Cardinal Health today reported fiscal year 2013 second-quarter revenue of $25.2 billion and a 15 percent increase in non-GAAP diluted earnings per share (EPS) from continuing operations to $0.93.
In addition, the company tightened its fiscal 2013 outlook for non-GAAP diluted EPS from continuing operations to $3.42 to $3.50, which represents the top half of the prior guidance range.
"We've now completed a strong first half to our fiscal 2013 with a good second-quarter performance. While continued brand-to-generic conversions and the previously announced movement of the Express Scripts contract drove a revenue decline in the Pharmaceutical segment, excellent performance from our generic programs and new customer wins fueled profit gains," said George Barrett, chairman and chief executive officer of Cardinal Health. "And, despite continued procedural softness in the industry, our Medical segment reported double-digit growth this quarter. With our performance in the first six months of fiscal 2013, we are now guiding to the top half of our prior non-GAAP EPS range."
Q2 FY13 SUMMARY
https://ir.cardinalhealth.com/releasedetail.cfm?ReleaseID=737852
CAH Chart
https://bigcharts.marketwatch.com/advchart/frames/frames.asp?show=&insttype=Stock&symb=cah&time=6&startdate=1%2F4%2F1999&enddate=1%2F8%2F2012&freq=1&compidx=aaaaa%3A0&comptemptext=&comp=&ma=4&maval=9+15+50&uf=7168&lf=1&lf2=4&lf3=2&type=4&style=320&size=3&timeFrameToggle=false&compareToToggle=false&indicatorsToggle=false&chartStyleToggle=false&state=11&x=0&y=0
Analyst Estimates
https://www.marketwatch.com/investing/stock/cah/analystestimates